IRONWOOD PHARMACEUTICALS, INC. Repayments of Convertible Debt
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Repayments of Convertible Debt of $200.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2024-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2024-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2022-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2022-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2024 was $200.00M.
- IRONWOOD PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2022 was $120.70M.
- IRONWOOD PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2019 was $227.34M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $200.00M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $200.00M 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $200.00M 10-Q · filed 2025-08-11 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $120.70M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $120.70M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $120.70M 10-Q · filed 2023-08-09 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $227.34M 10-K · filed 2022-02-18 | ||
| 2019-09-30 | $227.34M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |